Skip to main content

Table 4 Association between IgG and/or IgM seropositivity and clinical variables

From: Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis

Main features

IgG and/or IgM+

IgG and IgM−

n

p-value*

OR

95% CI

Gender

 Male

11

350

885

0.01

0.41

0.21–0.82

 Female

37

487

Age (years)

 < 70

31

579

885

n.s

1.23

0.67–2.26

 ≥ 70

17

258

Cancer stage

 0–III

12

123

804

0.04

0.48

0.24–0.97

 IV

30

639

ECOG performance status

 0

25

484

793

n.s

1.16

0.61–2.20

 1–4

16

268

Lymphopenia

 Yes

5

87

755

n.s

1.06

0.41–2.79

 No

34

629

Leukopenia

 Yes

6

85

764

n.s

1.38

0.56–3.36

 No

33

640

  1. n number of patients, OR odds ratio, n.s not statistically significant
  2. *The p-values represent χ2 tests of independence indicating associations between SARS-CoV-2 IgG and/or IgM seropositivity and categorical clinical variables (statistically significant p < 0.05)